ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulins, Intravenous

Also written as “NPB-01”, “TAK-881” and “IVIG”.

Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.

Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201783 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only203 open or runningphase 4since Apr 12, 2017Sep 8, 2005May 16, 2028phase 3 · NCT06076642
Grifolsits history only172 open or runningphase 4since Oct 24, 2011Sep 13, 2005Dec 31, 2027phase 3 · NCT07540221
Nihon Pharmaceuticalits history only80 open or runningphase 3since Jul 27, 2011Dec 11, 2008none ahead
Octapharma61 open or runningphase 3since Nov 11, 2009Nov 11, 2009Nov 2026phase 3 · NCT04640142
CSLits history only51 open or runningphase 3since Oct 12, 2011Oct 12, 2011May 6, 2029phase 2 · NCT07048262
Kedrionits history only53 open or runningphase 3since Apr 16, 2012Apr 16, 2012Dec 2026phase 3 · NCT07059000
Japan Blood Products Organizationits history only40 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
GC Biopharmaits history only31 open or runningphase 3since Jul 26, 2011Jul 26, 2011none ahead
Prothya Biosolutionsits history only30 open or runningphase 4since Aug 29, 2007Aug 29, 2007none ahead
Azidus Brasilits history only22 open or runningphase 3since Sep 19, 2023Sep 19, 2023Sep 2028phase 3 · NCT06150833

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Octapharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2009First study: phase 3 study in Primary Immunodeficiency DiseasesFirst studyNCT01012323 · 51 enrolled · United States
  2. Oct 6, 2010Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT01225276 · 2 enrolled
  3. Mar 9, 2011Phase 3 study in Primary Immunodeficiency DiseasesNCT01313507 · 21 enrolled · United States
  4. May 5, 2011Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT01349790 · 40 enrolled · Germany
  5. Dec 16, 2015Phase 3 study in Chronic Inflammatory Demyelinating Poly(Radiculo)NeuropathyNCT02638207 · 142 enrolled · Bulgaria, Canada, Czechia and more
  6. Nov 17, 2020Phase 3 study in Primary Immunodeficiency DiseasesNCT04640142 · 50 enrolled · United States, Germany, Hungary and more
  7. Nov 9, 2026Primary completion moved from 2026-09 to 2026-11Date moved laterphase 3 · +2 months · NCT04640142

Ahead

  1. Nov 2026Primary completion: phase 3 study in Primary Immunodeficiency DiseasesNCT04640142

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Octapharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04640142Primary Immunodeficiency Diseases · United States, Germany, Hungary and more3Active, not recruitingNov 202650
NCT02638207Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy · Bulgaria, Canada, Czechia and more3CompletedSep 5, 2019142
NCT01349790Purpura, Thrombocytopenic, Idiopathic · Germany3CompletedJul 201340
NCT01313507Primary Immunodeficiency Diseases · United States3CompletedSep 201221
NCT01225276Polyradiculoneuropathy, Chronic Inflammatory Demyelinating3TerminatedOct 20122
NCT01012323Primary Immunodeficiency Diseases · United States3CompletedJun 201251

How it is read

Names in the registry

  • “NPB-01”, 7 entries
  • “TAK-881”, 6 entries
  • “IVIG”, 6 entries
  • “Kedrion IVIG 10%”, 4 entries
  • “GB-0998”, 4 entries

Codes read as this program: TAK881, GC5107, GB0998.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.